► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
UK drugmaker AstraZeneca is in talks to acquire cancer drug developer Acerta Pharma, possibly for more than $5bn. Lex’s Oliver Ralph and Jonathan Eley discuss the challenges AstraZeneca has faced in recent years and why the potential takeover is important.
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
